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The glucocorticoid receptor (GR) is a member of the nuclear receptor
superfamily, which controls programs regulating cell proliferation,
differentiation, and apoptosis. We have identified an unexpected role
for GR in mitosis. We discovered that specifically modified GR species
accumulate at the mitotic spindle during mitosis in a distribution that
overlaps with Aurora kinases. We found that Aurora A was required
to mediate mitosis-driven GR phosphorylation, but not recruitment of
GR to the spindle. GR was necessary for mitotic progression, with
increased time to complete mitosis, frequency of mitotic aberrations,
and death inmitosis observed following GR knockdown. Complemen-
tation studies revealed an essential role for the GR ligand-binding
domain, but no clear requirement for ligand binding in regulating
chromosome segregation. The GR N-terminal domain, and specifically
phosphosites S203 and S211, were not required. Reduced GR expres-
sion results in a cell cycle phenotype, with isolated cells from mouse
and human subjects showing changes in chromosome content over
prolonged passage. Furthermore, GR haploinsufficient mice have an
increased incidence of tumor formation, and, strikingly, these tumors
are further depleted for GR, implying additional GR loss as a conse-
quence of cell transformation. We identified reduced GR expression in
a panel of human liver, lung, prostate, colon, and breast cancers. We
therefore reveal an unexpected role for the GR in promoting accurate
chromosome segregation during mitosis, which is causally linked to
tumorigenesis, making GR an authentic tumor suppressor gene.
glucocorticoid receptor | mitosis | aneuploidy | DNA damage | cancer
Glucocorticoids (Gcs) act through the glucocorticoid receptor(GR), a member of the nuclear hormone receptor super-
family, and a ligand-activated transcription factor (1–4). The GR is
ubiquitously expressed and regulates energy metabolism, immunity,
and cell fate decisions. The quiescent GR resides in the cytoplasm in
a complex with heat shock proteins and immunophilins, attached to
the microtubule architecture of the cell in a heat shock protein 90-
dependent manner (5). Ligand binding drives GR transformation,
involving N-terminal phosphorylation on S203 and S211 and rapid
translocation to the nucleus requiring attachment to dynein by heat
shock protein 90, immunophilins, and dynamitin (6). Once in the
nucleus, GR binds directly to DNA to regulate transcription, or
tethers to other DNA-bound transcription factors, such as nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and
activator protein 1 (AP1), to regulate their function (7–10).
In mitosis, GR is phosphorylated on both S203 and S211, but
in a ligand-independent manner (11), and more comprehensive
phosphoproteomic analyses identify the presence of multiple
N-terminal GR phosphoforms in purified mitotic spindle fractions
(12). Although altered GR function in mitosis has been shown
(11, 13, 14), the kinases responsible and cellular consequences
have not been defined. The role of GR in cancer has received
little attention beyond acute lymphoblastic leukemia, in which
GR is powerfully proapoptotic (15). However, GR inhibits ex-
pression of cyclin D and augments expression of cyclin-dependent
protein kinase inhibitors p21 and p27 to effect cell cycle slowing or
arrest in a cell type-specific manner (16).
We now define a role for GR in regulating mitosis using, at
least in part, nontranscriptional mechanisms. Loss of GR results
in a robust mitotic phenotype, with aberrant chromosome seg-
regation, accumulation of chromosome complement defects, and
death in mitosis, with the extent of cell survival or death varying
by cell type and model. Moreover, GR haploinsufficient mice
develop tumors with age. Analysis of common human cancers
revealed frequent cell type-specific loss of GR expression, im-
plying an important causal relationship between GR and ma-
lignant transformation or progression.
Results
We profiled the GR interactome (1,696 proteins) using immune
enrichment and MS methods, and compared the list of GR
interacting proteins with the mitotic spindle proteome (17). This
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approach identified GR binding to complexes involving 478 of
the 795 known protein components of the mitotic spindle (Fig.
1A and SI Appendix, Fig. S1), including both CENP-E and
BUB3, which are required for spindle checkpoint function (18,
19). Analysis of purified mitotic spindle fractions by immuno-
blotting using specific phospho-GR and pan-GR antibodies
revealed PS203 and PS211 modified GR species (Fig. 1B). The
presence of multiple GR protein species on immunoblots is
frequently seen, and may result from alternate protein isoforms
or posttranslational modification. Phosphatase treatment did not
result in loss of the additional bands, indicating that the mobility
shift is not due to differential phosphorylation (SI Appendix,
Fig. S2).
Immunofluorescence analysis confirmed GR localization to the
mitotic spindle, with particular enrichment at the centrosomes in
metaphase and anaphase cells (Fig. 1C and SI Appendix, Fig. S3).
The mitotic distribution of GR to the spindle was also demon-
strated using another antibody raised against a different GR
epitope (SI Appendix, Fig. S4), was sensitive to knockdown with
GR-specific siRNA (SI Appendix, Fig. S5), and was also seen
using an epitope-tagged (HaloTag) GR (Fig. 1 D and E). Analysis
of Halo-GR–transfected cells showed a heterogeneous sub-
cellular GR localization in asynchronous fixed cells, which visu-
alizes both soluble and cytoskeletal-bound GR (total GR
fraction; SI Appendix, Fig. S6A). A predominantly nuclear dis-
tribution was seen in permeabilized and washed-out cells fol-
lowing depletion of the soluble fraction (SI Appendix, Fig. S6A).
The mitosis-specific distribution of Halo-GR was similar to
that seen for endogenous GR (Fig. 1E and SI Appendix, Fig.
S6B), reinforcing the specificity of GR recruitment to the
mitotic spindle.
Previously, analysis revealed distinct subcellular distributions
for PS203GR and PS211GR (20), and because both are enriched
in mitosis, we tracked both phosphospecies through mitosis. We
find PS203GR at the centrosomes, showing an overlapping dis-
tribution with the centrosome marker γ-tubulin (21) throughout
mitosis (SI Appendix, Fig. S7). PS211GR also showed clear foci
at the centrosomes, with additional signal overlapping with
CREST-marked kinetochores (22) (SI Appendix, Fig. S8). To
control for antibody specificity, we used multiple siRNA species,
which confirmed localization of total GR, and both PS203GR
and PS211GR at the centrosome (SI Appendix, Figs. S5B, S7B,
and S8B). Although GR is known to interact with the kineto-
chore protein Ska2 (23, 24), the distribution of PS211GR over-
lying the condensed chromosomes and kinetochores was not
consistently lost with both GR siRNAs (SI Appendix, Figs. S8B
and S9), suggesting that this immunoreactivity may be due to
cross-reaction with another phosphorylated protein. Aligned
surface plots of the three GR antibodies suggest robust enrich-
ment of total GR and both GR phosphoforms to centrosomes
(SI Appendix, Fig. S9).
The distribution of GR therefore overlaps with components of
the microtubule organizing center, which is a site of Aurora ki-
nase activity. The distribution of phospho-GR (both PS203GR
and PS211GR) on the centrosome overlaps with Aurora A (SI
Appendix, Fig. S10A). Therefore, we tested Aurora kinase in-
hibition, initially with tozasertib (which inhibits both Aurora A
and Aurora B with a similar IC50). Tozasertib virtually abolished
mitotic GR phosphorylation on both S203 and S211 (SI Appen-
dix, Fig. S10B).
Immunofluorescence of tozasertib-treated cells demonstrates
that reduced PS203GR and PS211GR is not a consequence of
mitotic exit but that mitotic cells (highlighted with asterisks in SI
Appendix, Fig. S10C) are no longer enriched for GR phosphor-
ylation relative to surrounding interphase cells. Inhibition of
Aurora kinases disrupted normal spindle formation but did not
prevent association of the GR with α-tubulin foci (SI Appendix,
Fig. S10D), suggesting that phosphorylation of GR occurs sub-
sequent to spindle targeting. If phosphorylation of GR at S203
and S211 occurred subsequent to spindle recruitment, then se-
lective inhibition of Aurora A, but not Aurora B, would be
predicted to abolish this modification because GR and Aurora A
colocalize on the centrosome, and this effect was clearly seen (SI
Appendix, Fig. S10E).
Identification of modified GR species at the mitotic spindle and
regulation of GR modification downstream of Aurora A suggest
a possible role for GR in mitosis. We next investigated whether
knockdown of GR expression could affect chromosome segrega-
tion during mitosis in live cells using the expression of H2B-GFP
as a chromosome marker. GR knockdown delayed the mean time
from nuclear envelope breakdown to anaphase onset (from 76 to
102 min; Fig. 2A, SI Appendix, Fig. S11, and Movies S1–S4). The
delay in completion of mitosis appeared to be due to defective
chromosomal alignment/segregation because there was also a sig-
nificant increase in abnormal anaphase cells and death in mitosis
(Fig. 2B). Analysis of a cross-sectional population of targeted cells
suggested that loss of GR expression resulted in a significant ac-
cumulation of cells in metaphase (Fig. 2C), further supporting
a role for GR in facilitating metaphase/anaphase transition.
We also find increased numbers of cells with disorganized or
multipolar spindles (Fig. 2D and SI Appendix, Fig. S11C) and
micronuclei in interphase cells (Fig. 2E). These aberrant events
were rescued by “adding back” siRNA-resistant GR (Fig. 2 D
and E), confirming the specificity of effect.
To inform the mechanism underlying GR rescue of mitotic
progression, a series of complementation studies were performed.
We engineered domain deletant, phosphodeficient, and tran-
scriptionally compromised GR constructs (Fig. 3A and SI Ap-
pendix, Fig. S12) and transfected them into a HeLa Flp-In TRex
host cell line to generate a panel of eight stable cell lines with
doxycycline-regulated GR expression. We used a GR siRNA that
targeted the 3′ UTR to down-regulate endogenous GR selectively
(siRNA11; SI Appendix, Fig. S5 B–D) and then rescued GR ex-
pression by the addition of doxycycline (Fig. 3B). We again saw
a cell cycle phenotype following GR knockdown, further sup-
porting the observations above (Fig. 3C).
GR lacking either the N-terminal sites or phosphosites (ΔAF1GR,
S203AGR, and S211AGR) was still efficient at rescuing the
cell cycle phenotype (Fig. 3D). Although overexpression of
transcriptionally impaired and DNA-binding domain deletant
GR (R477C and ΔDBDGR) provided significant rescue, it was
Fig. 1. GR enriches to the mitotic spindle. (A) GR interacting proteins were
compared with a published spindle proteome that identifies interaction of GR
with a number of components of the mitotic machinery. (B) Mitotic spindles
were purified and immunoblotted for α-tubulin, GR, PS203GR, and PS211GR.
(C) HeLa cells were permeabilized and then fixed and immunolabeled for
α-tubulin and GR. Metaphase and anaphase cells are shown. (D) HeLa cells
were transfected with either Halo or Halo-GR. Twenty-four hours later, cells
were treated with vehicle (Veh) or nocodazole (Noc) for 16 h or with 100 nM
dexamethasone (Dex) for 1 h and then lysed and immunoblotted for GR,
Halo, or α-tubulin. (E) HeLa cells were transfected with Halo-GR, per-
meabilized, and then fixed and immunolabeled for α-tubulin and Halo. DNA
was counterstained with Hoechst. (Scale bars: 10 μm.)
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noted that the efficiency of rescue of ΔDBDGR was less than
full-length GR (Fig. 3D).
Only loss of the GR ligand-binding domain (ΔLBDGR) sig-
nificantly impaired rescue of the mitotic phenotype (impaired
rescue was not due to inefficient expression, as shown in Fig. 3D,
Inset). Interestingly, a point mutation, C736SGR, which renders
the GR resistant to endogenous ligands (SI Appendix, Fig. S12C),
also provided efficient rescue (Fig. 3D), suggesting that ligand
binding or GR activation is not necessary for the rescue pheno-
type but, rather, that the ligand-binding domain may provide the
surface for an important protein–protein interaction. We also
examined the effect of GR knockdown on a panel of GR target
genes under the same experimental conditions. A single transcript
of the 15 measured genes showed transcriptional regulation fol-
lowing GR knockdown (SI Appendix, Fig. S13), making a tran-
scriptional role for the GR unlikely. These data, coupled with the
spindle localization of GR and functional interaction with mitotic
proteins and kinases, support the hypothesis that the unliganded
GR, and specifically its ligand-binding domain, plays a direct role
in regulating mitotic spindle function.
To explore this cell cycle phenotype in vivo, we first analyzed
mouse embryonic fibroblasts derived from GR-deficient (GR−/−)
mice, which are not viable due to perinatal mortality. Initial
analysis of DNA content by fluorescence-activated cell sorting
identified no evidence of aneuploidy (>4n) in low-passage cells,
but chromosome counts demonstrated a trend toward chromo-
somal aberrations in GR-null cells (29% vs. 22% of cells with
a normal chromosome complement in GR+/+ and GR−/− cells,
respectively; P = 0.055). However, GR-null cells showed clear
protection from aneuploidy at high passage (Fig. 4A). This
complex phenotype may result from GR loss driving cells to
death in mitosis, as seen above with acute GR knockdown.
We also investigated mild genotoxic challenge, BrdU treatment,
in GR+/− mice (Fig. 4B). Accumulation of dsDNA breaks is a
consequence of aberrant chromosome segregation (25) and
offers a robust and enduring “mark” of such anomalies. We ana-
lyzed livers from BrdU-infused GR+/+ and GR+/− mice and found
evidence of more dsDNA breaks (γ-H2AX staining) in BrdU-
treated GR+/+ animals compared with the GR+/− animals (26).
We also analyzed aged GR+/− mice (100 wk of age) and found an
increased incidence of dsDNA breaks in both the liver and colon
(Fig. 4C). In liver, DNA damage was identifiable throughout the
tissue, whereas in colon, it appeared to be confined to the epi-
thelial cell layer, which is consistent with sites of the highest GR
expression in healthy tissue (SI Appendix, Fig. S14).
In our analysis of tissue from aged GR haploinsufficient mice,
we found an increase in microtumors in the GR-deficient livers
(Fig. 4D) and lungs (Fig. 4E) compared with WT. No differences
in premature mortality within the colony were noted, supporting
a requirement for additional accumulated genomic damage over
time for malignant transformation. We observed that the tumors
were further depleted for GR expression compared with sur-
rounding tissue, providing strong evidence linking GR expression
with tumorigenesis in vivo (Fig. 4 D and E).
Our data suggest that loss of GR expression may contribute to
tumorigenesis by impairing accurate chromosome segregation.
Fig. 2. Reduction of GR expression delays anaphase transition and increases
the frequency of chromosomal abnormalities. HeLa cells stably expressing
H2B-GFP were transfected with 50 nM nontargeting (NT) or GR-specific
(GR6) siRNA, and mitotic events were imaged in real time [values depict
minutes from an arbitrary start point (t0)]. Representative fields are shown.
(A) Images were scored for average time to completion of mitosis, frequency
of abnormal mitotic events, and death in mitosis. (B) Ten fields were tracked
per replicate. Graphs show mean ± SEM from four independent duplicate
experiments. Movies S1–S6 are provided as supplementary information. NEB,
nuclear envelope breakdown. (C–E) HeLa cells were treated with 50 nM NT
or two different GR-specific (GR5 and GR6) siRNAs, together with siRNA-
resistant GR plasmid (pcDNA3GR) or empty vector control (pcDNA3) for 48 h,
and then fixed and labeled with an α-tubulin–specific antibody and Hoechst
DNA dye counterstain. Cells were imaged and scored for mitotic phase
(C) and for evidence of mitotic abnormalities, including spindle deformities (D)
and interphase micronuclei (E, yellow arrowhead). Graphs depict mean ± SEM
of at least three independent triplicate experiments. Data were analyzed by
the Mann–Whitney test or ANOVA, where *P < 0.05. (Scale bars: 10 μm.)
Fig. 3. GR regulation of chromosome segregation requires the GR ligand-
binding domain. (A) Schematic showing GR deletant and mutant constructs.
Stable HeLa Flp-In TRex-GR cells were transfected with NT or GR-specific
siRNA (GR11) and then treated with 5 μM doxycycline (Dox). Forty-eight
hours later, cells were lysed and immunoblotted for GR (B) or fixed and
nuclei counterstained with Hoechst (C). (D) Aberrant mitoses were scored
and quantified. The graph depicts mean ± SEM of three independent trip-
licate experiments. (Inset) Image shows expression of ΔLBDGR. Data were
analyzed by ANOVA, where **P < 0.01. DBD, DNA-binding domain; FLGR,
full-length GR; LBD, ligand-binding domain; NTD, N-terminal domain. (Scale
bars: 10 μm.)
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To explore this possibility in human cells, we first analyzed B
lymphoblasts from patients with GR haploinsufficiency [caused
by a frameshift mutation in the GR gene (27)]. Chromo-
some complement was significantly lower in cells from three
haploinsufficient individuals compared with an unaffected family
member (Fig. 5 A and B and SI Appendix, Fig. S15). We also ex-
amined GR expression in a comprehensive panel of human cancers
and discovered significantly reduced transcript across all tumors
(Fig. 5C). We find significant down-regulation of GR transcript in
liver, lung, and prostate (Fig. 5D); colon (Fig. 5E); breast (Fig. 5F);
and esophageal, ovarian, and endometrial cancers (SI Appendix,
Fig. S16A). We confirmed loss of GR protein in human colon and
breast cancer tissue arrays by immunohistochemistry (Fig. 5 G and
H and SI Appendix, Fig. S16B). Interestingly, we find that the effect
is tissue-specific, with no significant difference in GR expression
seen in human bone or gastric cancers (SI Appendix, Fig. S17A)
and a significant up-regulation of GR transcript seen in pancreatic
and renal cancers (SI Appendix, Fig. S17B), along with increased
GR protein (SI Appendix, Fig. S17C).
Even within a single tissue, different tumor subtypes showed
variation in GR expression, indicating a major cell type-specific
effect (SI Appendix, Fig. S18). There were no sex-related differ-
ences in GR expression (SI Appendix, Fig. S19A) and no correlation
between GR and estrogen receptor (ERα) expression across all
breast cancer subtypes or with androgen receptor (AR) expression
in prostate cancer (SI Appendix, Fig. S19B).
Discussion
The GR plays a key role in energy metabolism, immunity, and
cell fate determination. Now, our data identify a role in mitotic
progression and chromosome segregation. The distribution of
GR through metaphase and anaphase overlaps with the spindle
centrosome, which plays a major role in coordinating accurate
chromosome segregation (28–32). Moreover, under conditions
not permissive for GR transcriptional effects, there was a clear
biological role, implying a nontranscriptional mechanism of action.
Mitosis is a dynamic process, controlled by the activity of mul-
tiple kinases, with attendant modification of proteins facilitating
strict checkpoint control. Aurora kinases are master regulators of
both centrosome and checkpoint control function. Aurora A is
found at centrosomes in early mitosis and controls centrosome
maturation, centriole separation, and chromosome alignment
(33), whereas accurate targeting of Aurora B to the chromosomes,
Fig. 4. GR haploinsufficiency increases DNA damage and tumor formation
in vivo. (A) Low-passage (p4) GR+/+ and GR−/− mouse embryonic fibroblasts
(MEFs) were analyzed for DNA content by fluorescence-activated cell sorting
(FACS) and also metaphase spread assays. High-passage (p20) GR+/+ and GR−/−
MEFs were analyzed for DNA content by FACS. (B) Livers from 12-wk-old
GR+/+ and GR+/− mice infused with BRdU were stained for BRdU or γ-H2A.X
as an indicator of DNA damage. BRdU or H2A.X staining is shown in brown,
and nuclei are counterstained with toluidine blue. A minimum of 1,000 cells
for each section were scored from three to four different animals. (C) Liver
and colon from 100-wk-old GR+/+ and GR+/− mice were analyzed for γ-H2A.X
as an indicator of DNA damage. A minimum of 10,000 cells were scored for
each section from two to four different animals. (D) Immunohistochemistry
of serial liver sections from a GR+/− mouse labeled for Ki-67 and GR. (Insets)
Higher magnification images are shown. Liver tumors from multiple animals
are quantified. (E) Immunohistochemistry of serial lung sections from a GR+/−
mouse labeled for Ki-67 and GR. Lung tumors from multiple animals are
quantified. The graph shows mean ± SEM values. (Magnification: B, 10×;
C, 40×; D and E, 2.5×.) Data were analyzed by the Mann–Whitney test, where
*P < 0.05 and **P < 0.01.
Fig. 5. GR is down-regulated in human cancers. B lymphocytes from a family
with GR haploinsufficiency (A) were analyzed for chromosome complement by
metaphase spread assay (B). Chromosome counts show counts for 150 cells from
three independent passages (p5–p8). (C ) Microarrays of tumor and
matched normal tissues from 1,314 patients were analyzed for GR transcript.
(D) GR transcript in liver, lung, and prostate is shown. GR transcript and pro-
tein are shown for colon (E and G) and breast (F and H) cancers. (Magnifi-
cation: 20× .) Graphs depict median and interquartile range. n, number
of patient samples within each group. Data were analyzed by ANOVA, fol-
lowed by Tukey’s correction or the Mann–Whitney test, where *P < 0.05 and
**P < 0.001.
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and then to the spindle midzone and midbody, is essential for
maintaining microtubule/kinetochore attachments, and therefore
faithful chromosomal segregation (34). We find that GR is mul-
tiply phosphorylated in an Aurora A kinase-dependent manner.
GR phosphorylation by an Aurora kinase-dependent pathway
provides the mechanism explaining the tight coupling of ligand-
independent GR phosphorylation to cell cycle phase because the
maximal activity of these kinases occurs in mitosis.
To examine the functional role of GR during mitosis, we
performed GR knockdown studies, tracking cell division in real
time, and observed increased chromosome segregation errors
with evidence of spindle defects. Multipolar spindles can arise as
a consequence of failure of cytokinesis, centrosome amplifica-
tion, or loss of spindle pole integrity (35). Although we find
tetraploid cells following GR loss (Movie S3), our data suggest
that the majority of GR knockdown cells either progress through
mitosis with errors or die in mitosis. GR localizes to centrosomes
in both interphase and mitotic cells (36), making a possible role
for GR in controlling centrosome number in S-phase. However,
multipolarity occurs after normal bipolarization of the spindle
(Movies S4–S6), suggesting normal centrosome number at the
onset of mitosis. Loss of GR drives a significant delay in meta-
phase, followed by the acquisition of tripolar or tetrapolar
spindles, identifying loss of spindle pole integrity as a possible
consequence of reduced GR expression. Although it remains
unclear how the aberrant mitotic phenotype occurs, a model for
the generation of multipolar spindles independent of centrosome
amplification has recently been advanced, which lists likely
causes as cohesion fatigue, fragmentation of pericentriolar ma-
terial, or centriole disengagement (35).
However it arises, the spindle defects we observe following
loss of GR, including chromosome misalignment and multipo-
larity, drive chromosomal instability, causing either death in
mitosis or completion of mitosis and survival as an aneuploid
cell. GR may act at multiple stages to influence both mitosis and
the response to aneuploidy. Other tumor suppressors, including
p53, serve multiple roles to prevent mitotic errors in the first
instance, to correct such errors, or to promote apoptosis. The
impact of reduced GR expression may therefore be twofold:
increasing the frequency of mitotic segregation errors and failing
to induce apoptosis, thereby permitting cells to survive with an
abnormal chromosome complement.
We sought a mechanism explaining GR regulation of mitosis
using complementation. Our studies revealed that the GR li-
gand-binding domain was required for protection from mitotic
defects, and that other major domains, including the DNA-
binding domain and N-terminal domain, were dispensable. The
DNA-binding domain is predicted to be required for gene reg-
ulation and supports a nontranscriptional role for the GR in
mitosis. The N-terminal domain contains both S203 and S211,
which are phosphorylation targets downstream of Aurora A ki-
nase. However, loss of the entire domain or point mutation to
the Ser residues did not affect rescue. Furthermore, immuno-
fluorescence data show that GR localization to the spindle
occurs before phosphorylation. Taken together, our data suggest
that phosphorylation at S203 and S211 by Aurora A at the
spindle is not required for the regulation of mitosis.
To test the role of target gene transcription in GR mediation of
mitosis further, we examined a broad panel of known GR target
genes, some involved in mitotic progression. Of the 15 genes
studied, only one showed a small, but significant, change in re-
sponse to loss of GR, under the same culture conditions used for
the rescue experiments, suggesting that the GR is only minimally
transcriptionally competent. To test the requirement for tran-
scriptional competent GR, we used a ligand-binding domain
point mutant, which renders the GR severely resistant to en-
dogenous ligands, such as those ligands found in serum or in
cultured human cells. This GRC736S mutant also efficiently
rescued the cell cycle phenotype, further suggesting only a mini-
mal role for conventional GR transcription in this pathway.
A late consequence of such aberrant mitosis, in the event that
death in mitosis is avoided, is survival of aneuploid cells with
accumulation of DNA damage (37). We identified a complex cell
cycle phenotype resulting from loss of GR expression. We found
spontaneous DNA damage/aneuploidy in aged GR hap-
loinsufficient animal tissues and in cells harvested from people
with GR haploinsufficiency. In addition, we identified that in
GR-null MEFs subject to prolonged passage, or in GR hap-
loinsufficiency in response to genotoxic challenge, there was
apparently paradoxical protection from accumulation of DNA
damage, an effect we ascribe to increased death in mitosis. In-
deed, a similar phenotype of DNA damage response was
reported in CENP-E haploinsufficient mice. Loss of CENP-E
drives loss of only a few chromosomes, which permits cells to
persist in an aneuploid state; however, with additional stress,
such as a genotoxic challenge, cells accumulate more damage
and are driven to apoptosis, thereby paradoxically protecting
from aneuploidy. In this way, loss of CENP-E increases the in-
cidence of lymphoma and spontaneous lung tumors but provides
protection against chemical tumorigenesis (38).
We find significantly more tumors in mice that are hap-
loinsufficient for GR, and therefore propose that loss of GR may
be a cause, and not simply a consequence, of cellular trans-
formation. Indeed, it is striking that there is marked further loss
of GR protein detected within the tumors, further supporting
a tumor suppressor role for the GR. The role of GR in cancer
has received some attention, but, to date, no clear phenotype has
emerged. Gc use, and therefore activation of GR, has been
linked with an increased risk of developing skin and bladder
cancer (37, 39). However, none of the small number of patients
with GR genetic defects and familial Gc resistance has de-
veloped cancer. We now provide evidence for GR in human
malignancy, with a strong negative association in GR expression
seen across a broad panel of, but not all, human cancers.
We have previously shown reduced GR expression in small-
cell lung cancer (40–42), and methylation of the GR promoter,
with loss of GR expression, has been reported in colorectal
cancer (43). In addition, the GR has recently emerged as a can-
didate tumor suppressor gene in breast cancer (44). Earlier
studies had found GR somatic aberrations with an attendant
altered transcriptional profile in triple-negative breast cancer
(45), and more recently, a complex association between GR
expression in breast cancer, predicting either a poor or good
prognosis dependent on subtype (46). Taken together our find-
ings reveal an important role for GR in regulating mitotic pro-
gression, aneuploidy, and tumorigenesis.
Our findings now show that GR function regulates accurate
mitotic progression, with clear implications for human health. Gcs
are often used in combination with cancer therapies, largely due to
their antiinflammatory and antiemetic properties (47). Such Gc
treatment activates GR and may induce cell cycle arrest through
a transcriptional mechanism or apoptosis in a cell type-dependent
manner. Gcs have also been reported to oppose chemotherapy
induction of apoptosis in a tissue-specific manner, providing fur-
ther evidence for a critical role in cell fate determination (48). Our
findings now add a previously unidentified perspective to GR
action in cell division, affecting mitotic spindle function. Given the
key role of the ligand-binding domain in mediating the cell cycle
effect, it may be that this action can be targeted by specific ligands,
potentially opening up new therapeutic approaches to treat
common cancers.
Materials and Methods
Detailed information describing antibodies, plasmids, cell lines, and animal
procedures used in this study is provided in SI Appendix. Immunoblot analysis
and reporter gene assays were performed as described by Matthews et al.
(11). Purification of mitotic spindle fractions was as described by Sauer et al.
(17), real-time fluorescent cell imaging was performed as described by
Trebble et al. (49), and quantitative PCR analysis was as described by Poolman
et al. (50). Additional methods for immunofluorescence, GR proteomics,
immunohistochemistry, and gene arrays are provided in SI Appendix.
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